Alpine immune sciences, inc. (ALPN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Net Income (Loss) Attributable to Parent

-5,533

-6,140

-11,475

-11,856

-12,381

-11,135

-12,139

-7,907

-5,306

-4,318

2,122

-3,598

-1,989

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,838

-

-6,089

-5,852

-4,314

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense

135

124

115

-76

305

109

109

90

80

76

64

55

46

-35

38

36

30

-

16

15

16

Amortization of premium/discount on investments

41

86

89

53

132

216

85

368

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

44

41

32

32

35

38

43

44

44

44

43

0

0

-

-

-

-

-

-

-

-

Deferred income tax

-

-

-

-

-

0

0

-253

-52

-204

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

986

780

825

682

754

731

544

523

511

310

229

247

52

-2,182

852

700

707

625

348

219

151

Changes in operating assets and liabilities:
Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

134

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

623

-4,084

4,077

718

-303

144

-746

509

27

-

-

-

-

540

-682

237

-69

168

-427

2,730

-2,669

Right-of-use asset

147

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-4,005

-4,780

3,767

1,723

106

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

335

-

581

144

199

62

-1,098

914

202

-558

204

-1,290

1,709

Deferred revenue

-1,091

-634

-39

2,108

0

-1

0

-240

-239

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities

287

70

121

-173

-213

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-738

-737

-

-

-

-

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

-

-

204

-

-749

425

406

-

-

-

-

-

-

-

-

Increase (Decrease) In Deferred Rent And Other Operating Liabilities

-

-

-

-

-

-

-

-

19

-

-10

-5

-7

-

-

-

-

-

-

-

-

Accrued direct program expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

95

133

1,054

98

-225

526

-88

Accrued employee benefits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

360

273

-963

339

359

462

305

Accrued other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

-25

-134

-

-

-

-5

Net cash used in operating activities

-9,694

-5,671

-10,575

-7,877

-11,223

-9,398

-7,372

-7,215

-4,431

-5,837

-4,686

-3,885

-2,164

-

-

-

-

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,011

-5,401

-5,726

-3,185

-4,895

Purchases of property and equipment

56

486

135

79

121

9

208

160

118

77

288

113

108

692

16

43

31

46

55

35

52

Purchase of short-term investments

4,914

5,076

14,502

26,508

13,296

9,655

21,818

4,353

37,037

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

18,100

-

-

-

31,125

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

-

-

-

-

-

-

37,800

48,626

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of short-term investments

0

0

0

0

1,391

0

0

-41,025

41,025

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

0

-

13,919

22,766

29,469

-

-

-

-

Proceeds from the sale of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from sales and maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22,200

28,650

27,550

-

-

-

-

Net cash provided by investing activities

13,130

4,388

10,863

-17,587

19,099

9,136

15,774

3,338

3,870

1,855

-31,437

-113

-108

-

-

-

-

-

-

-

-

Financing activities
Proceeds from borrowings, net of issuance costs

5,000

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Issuance of Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

0

17,000

16,666

4,000

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and common stock warrants

-

-

-

-

-

-

-

-

-

-

1

0

21

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,950

-27,225

-35,136

-35

-52

Proceeds from sale of common stock, net of offering costs

0

0

0

-20

23,618

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of debt

0

0

333

500

500

500

500

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

0

2

0

7

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

5,000

0

1,646

-509

23,118

-500

-498

0

7

0

17,001

21,666

4,021

-

-

-

-

-

-

-

-

Effect of exchange rate on cash, cash equivalents and restricted cash

-113

-

-

-

-14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents and restricted cash

8,323

-1,272

1,927

-25,969

30,980

-762

7,904

-3,877

-554

-3,982

-19,122

17,668

1,749

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

752

-614

-8,961

-32,564

-42,966

77,656

-4,947

Supplemental Information
Discount in connection with issuance of debt

335

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

73

73

30

32

35

38

39

38

34

-

-

-

-

-

-

-

-

-

-

-

-

Recognition of right-of-use asset

0

-494

-90

10,874

883

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-